Steroid Tapering Protocol

Introduction to Steroid Tapering

The American College of Physicians recommends that for any patient receiving more than 7.5 mg prednisone equivalent daily for more than 3 weeks, gradual tapering is mandatory to prevent adrenal insufficiency 1
HPA axis suppression should be anticipated in any patient receiving >7.5 mg daily for >3 weeks, with a strength of evidence based on clinical guidelines 1, 2

The optimal approach involves rapid reduction from high doses to 10 mg/day within 4-8 weeks, then significantly slower tapering once approaching physiological doses, as recommended by the American College of Rheumatology 1
Reduce by 5-10 mg per week until reaching 10 mg/day, primarily addressing disease control rather than HPA axis recovery, with a moderate strength of evidence 1, 3

For polymyalgia rheumatica, initial dose: 12.5-25 mg/day, taper to 10 mg/day within 4-8 weeks, then reduce by 1 mg every 4 weeks until discontinuation, based on guidelines from the European League Against Rheumatism 1, 3
For inflammatory myopathies, start at 60-80 mg/day, taper by 10 mg every 2 weeks to 30 mg/day, then 5 mg every 2 weeks to 20 mg/day, with a high strength of evidence from clinical trials 1, 3
For ABPA with bronchiectasis, start at 0.5 mg/kg/day for 1-2 weeks, then alternate days for 6-8 weeks, with a moderate strength of evidence from respiratory guidelines 4

If disease flare occurs, immediately return to the pre-relapse dose and maintain for 4-8 weeks before attempting a slower taper, as recommended by the American College of Rheumatology 1, 3
Monitor disease activity markers every 4-8 weeks during first year of tapering, then every 8-12 weeks, with a high strength of evidence from clinical guidelines 3

All patients tapering steroids require supplemental glucocorticoids during acute illness or physiologic stress, with this requirement persisting up to 12 months after discontinuation, based on endocrinology guidelines 1, 3
For minor illness: double the current prednisone dose for 3 days, with a moderate strength of evidence from clinical experience 3

Check disease activity markers monthly during tapering phase, with a high strength of evidence from clinical guidelines 3
Monitor for both disease flare and adrenal insufficiency symptoms, with a moderate strength of evidence from clinical experience 1, 3

Never taper too rapidly from physiological doses (<10 mg/day)—this is when HPA axis recovery is most critical, as warned by the American College of Physicians 1, 2
Avoid abrupt discontinuation after prolonged therapy (>3 weeks), which causes higher relapse rates, with a high strength of evidence from clinical trials 2
Ensure adequate duration at each dose level—rushing through the taper increases failure risk, with a moderate strength of evidence from clinical guidelines 2
Monitor carefully after discontinuation, as inflammation may recur especially with abrupt cessation, with a high strength of evidence from clinical trials 7, 8